Application of domestic porcine antihuman lymphocyte immunoglobulin in allogeneic hemopoietic stem cell transplantation for severe aplastic anemia
10.3760/cma.j.issn.1673-4904.2019.01.007
- VernacularTitle:国产猪抗人淋巴细胞免疫球蛋白在重型再生障碍性贫血异基因造血干细胞移植中的应用研究
- Author:
Pu ZHANG
1
;
Kai FENG
;
Jie FU
;
Yan XUE
;
Cixian ZHANG
;
Lili XIANG
;
Jiale MA
;
Xiaolin LI
Author Information
1. 江苏省徐州市中心医院血液科 221009
- Keywords:
Anemia;
aplastic;
Antilymphocyte serum;
Hematopoietic stem cell transplantation;
Therapeutic uses
- From:
Chinese Journal of Postgraduates of Medicine
2019;42(1):22-25
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the efficacy of domestic porcine antihuman lymphocyte immunoglobulin (p-ALG) in the treatment of severe aplastic anemia (SAA) with allogeneic hemopoietic stem cell transplantation (HSCT). Methods The clinical data of 5 SAA patients who received allogeneic HSCT from January 2015 to May 2018 were retrospectively analyzed. The conditioning regimen included p-ALG + cyclophosphamide + fludarabine. The method of peripheral stem cell and bone marrow blood was used in allogeneic HSCT (the total amount of bone marrow blood was less than 400 ml and the puncture point was not replaced). The p-ALG related complications, post-transplantation hemopoietic stem cell reconstitution time and efficacy were recorded. Results Allergic reaction occurred in 1 patient when using p-ALG, and there was no serum reaction. Hemopoietic reconstitution was achieved in all the 5 patients. The time for neutrophilic granulocyte > 0.5 × 109/L was 11 to 17 d, and the time for platelet count > 20 × 109/L was 11 to 15 d after transplantation. The results of short-strand repeat polymerase chain reaction assays showed all complete donor chimera. Graft versus host disease occurred in 3 cases, and was successfully controlled by methylprednisolone and tacrolimus. The time for stopping red blood cell transfusion was 9 to 87 d. The patients were followed up for 1 to 37 months, and the patients all survived well. Conclusions The efficacy of p-ALG in SAA patients of allogeneic HSCT is affirmative, and the cost is obviously reduced. It is worthy of clinical use.
